Maze Therapeutics 'evaluating legal and business options' in response to US FTC block of Sanofi licensing agreement
MLex Summary: After the US Federal Trade Commission filed a complaint to block a licensing agreement between Sanofi and Maze Therapeutics for Maze's MZE001 Pompe disease therapy, Maze CEO Jason Coloma...To view the full article, register now.
Already a subscriber? Click here to view full article